



Oregon Bioscience Association

ADVOCATE. CULTIVATE. EDUCATE.

Chair Patterson
Vice Chair Hayden
Members of the Committee

May 7, 2025

Thank you for the opportunity to provide written testimony from The Oregon Bioscience Association “Oregon Bio”.

Oregon Bio represents a diverse group of organizations supporting Oregon’s biotech ecosystem, including researchers, entrepreneurs, large and small therapeutic, pharmaceutical and medical device developers and manufacturers. Oregon Bio opposes HB 2385.

Aside from imposing restrictions between private entities within state law, the bill attempts to influence a federal program in dire need of adjustment and accountability. Current evidence (and other testimony you’ve heard) demonstrates a shifting balance of 340b savings from the very patients the program seeks to support towards a broad range of entities using the benefits of 340b participation regardless of program intent. By diverting significant resources within the drug supply chain, this bill risks continued investment into the innovation and growth of Oregon’s bioscience sector. With little evidence that program growth is benefiting patients, there must be some impact of this wide sweeping bill.

HB 2385 potentially redirects millions of dollars that could be earmarked for investment in research & redevelopment or investment and partnership with our state’s emerging biotech companies. Instead, HB 2385 seeks to codify restrictions on entities that would prohibit protections and written agreements that ensure 340b savings, provided by drug manufacturers, reach the intended patients. Oregon must choose how to protect the best environment for health outcomes, equity and innovation. HB 2385 may not meet those goals without ensuring the integrity of the 340b program.

Furthermore, the bill could deter investment in our state’s bioscience initiatives. Investors seek stability and predictability, and the introduction of such restrictive measures sends a negative message about Oregon’s commitment to nurturing its bioscience sector by choosing some health care entities over others without certainty about the patient outcomes.

Oregon Bio advocates for regulations that are based on sound science and evidence. This bill lacks the necessary evidentiary foundation for restricting contracts between various entities. We believe that policy decisions should be grounded in thorough research and collaboration with industry stakeholders to ensure that they promote innovation rather than possibly hinder it.

In conclusion, the Oregon Bioscience Association urges lawmakers to reconsider HB 2385 and its broad application and whether this is the right approach to ensure affordable access to critical therapies for those who need it most.

Liisa Bozinovic

Liisa Bozinovic
Oregon Bioscience Association
Executive Director